March 27, 2014
The ongoing Molybdenum-99 (Mo-99) supply challenges faced by the nuclear medicine industry remain in effect. Based on currently available resources and projections for Mo-99 supply, Mallinckrodt Pharmaceuticals expects to meet standing customer orders for Technetium-99m throughout April. This outlook is based on the expectation of the Nuclear Research and consultancy Group (NRG) that the Dutch Mo-99 Production Facility (MPF) will be operational by mid-April. NRG is the licensee of the MPF, and Mallinckrodt operates the facility.
Click here for the full letter from Mallinckrodt Pharmaceuticals.